VP – Market Access & Value-Based Partnerships

Rune Labs has launched StrivePD Guardian, an AI companion for Parkinson's disease patients powered by Anthropic's Claude and trained on millions of hours of wearable data. The system provides personalised, real-time guidance on symptoms, medications and care goals. The platform uses specialised AI agents for medication education, symptom interpretation, evidence-based coaching, journaling and data visualisation. Unlike general-purpose AI tools, it analyses continuous wearable data and FDA-cleared symptom algorithms to deliver context-aware support tailored to Parkinson's fluctuating symptoms. StrivePD Guardian includes clinical safeguards and urgent symptom guidance directing patients to medical professionals when necessary. The app is now available on the App Store for all users, with AI chat access varying by plan. Healthcare providers can offer it through partner programmes for patient monitoring and care coordination.

Rune Labs appoints Digital Health Leader Adam Pellegrini to Board of Directors. Seasoned executive brings decades of experience in AI-driven health, digital therapeutics, and payor strategy to support Rune Labs' next phase of growth Rune Labs, the leader in precision medicine for neurology, today announced the appointment of Adam Pellegrini as an independent member of its Board of Directors. Pellegrini is a recognized leader in AI-driven digital health, with more than two decades of experience building and scaling platforms that bridge technology, patients, and healthcare systems. His background spans executive roles at Kaia Health, Jasper Health, CVS Health, Fitbit, Walgreens Boots Alliance, and other organizations that have shaped how digital tools support prevention, chronic disease management, and patient engagement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021141766/en/ Adam Pellegrini joins Rune Labs as an independent member of its Board of Directors Pellegrini is currently serving as CEO of AI-based musculoskeletal and pulmonary company Kaia Health, expanding access through strategic partnerships and reimbursement pathways. Before Kaia, he served as CEO and Board Member of Jasper Health, which provides virtual oncology care and patient navigation solutions used by thousands of individuals and caregivers. Earlier in his career, he served as SVP Enterprise Virtual Care & Consumer Health Innovation at CVS Health and General Manager & SVP at Fitbit (now part of Google), helping drive payor integration and digital health strategies that advanced large-scale adoption across employers and health plans. Pellegrini also served as Digital Health Leader & Vice President Marketing for the American Cancer Society, driving digital strategy for the entire organization. "Adam has a unique understanding of how digital health can create real value across the care continuum," said Brian Pepin, CEO of Rune Labs. "His experience scaling technology and building reimbursement partnerships over multiple sectors of healthcare will be invaluable as we expand the StrivePD ecosystem and strengthen our work with trial sponsors, clinicians, and payors." Pellegrini's appointment comes as Rune Labs is experiencing significant growth of its StrivePD platform, which helps improve how PD is managed and studied. StrivePD brings together data from the Apple Watch, clinical sources, and self-reported outcomes using AI-driven analysis to improve care management, giving people with PD (PwPD) and providers a clearer view of daily symptoms and treatment responses while improving access to innovative therapies. StrivePD also enhances how PwPD are identified, recruited, and monitored in clinical trials, enabling sponsors to design more precise studies and reduce operational inefficiencies. "Rune Labs is setting a new standard of care for how real-world data and digital tools drive innovation and results in neurological research and care, serving the entire ecosystem from individuals and clinicians to researchers, healthcare organizations, and payors," said Pellegrini. "That kind of connected insight enables smarter decisions and supports more sustainable models of care." About Rune Labs Rune Labs is an AI-led data analytics company for precision neurology, supporting care delivery and therapy development. StrivePD is the company's care delivery ecosystem for Parkinson's disease, enabling patients and their clinicians to better manage the disease by providing access to summarized objective and subjective data to improve treatment decisions, enhance disease management and connect patients to clinical trials. For therapeutics development, biopharma and medical device companies leverage Rune's technology, network of engaged clinicians and patients, and large longitudinal real-world datasets to expedite development programs. The company has received financial backing from leading investors such as Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures. For more information, please visit runelabs.io and strive.group. Media Contact Consort Partners for Rune Labs [email protected] View source version on businesswire.com: https://www.businesswire.com/news/home/20251021141766/en/ The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.